On Tuesday, Halozyme Therapeutics Inc (NASDAQ: HALO) was -2.05% drop from the session before settling in for the closing price of $60.62. A 52-week range for HALO has been $40.19 – $66.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 39.83%. When this article was written, the company’s average yearly earnings per share was at 23.77%. With a float of $122.23 million, this company’s outstanding shares have now reached $123.14 million.
Considering the fact that the conglomerate employs 350 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 80.8%, operating margin of 54.32%, and the pretax margin is 54.87%.
Halozyme Therapeutics Inc (HALO) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Halozyme Therapeutics Inc stocks. The insider ownership of Halozyme Therapeutics Inc is 1.06%, while institutional ownership is 99.59%. The most recent insider transaction that took place on Apr 28 ’25, was worth 271,467. In this transaction Director of this company sold 4,497 shares at a rate of $60.37, taking the stock ownership to the 28,611 shares. Before that another transaction happened on Apr 01 ’25, when Company’s Director sold 503 for $64.05, making the entire transaction worth $32,217. This insider now owns 33,108 shares in total.
Halozyme Therapeutics Inc (HALO) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 23.77% per share during the next fiscal year.
Halozyme Therapeutics Inc (NASDAQ: HALO) Trading Performance Indicators
You can see what Halozyme Therapeutics Inc (HALO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.22. Likewise, its price to free cash flow for the trailing twelve months is 15.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.43, a number that is poised to hit 1.20 in the next quarter and is forecasted to reach 7.20 in one year’s time.
Technical Analysis of Halozyme Therapeutics Inc (HALO)
Compared to the last year’s volume of 1.44 million, its volume of 1.4 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 62.43%. Additionally, its Average True Range was 2.17.
During the past 100 days, Halozyme Therapeutics Inc’s (HALO) raw stochastic average was set at 66.46%, which indicates a significant increase from 51.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.03% in the past 14 days, which was higher than the 28.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $60.81, while its 200-day Moving Average is $56.24. Nevertheless, the first resistance level for the watch stands at $60.50 in the near term. At $61.62, the stock is likely to face the second major resistance level. The third major resistance level sits at $62.68. If the price goes on to break the first support level at $58.32, it is likely to go to the next support level at $57.26. Should the price break the second support level, the third support level stands at $56.14.
Halozyme Therapeutics Inc (NASDAQ: HALO) Key Stats
There are 123,533K outstanding shares of the company, which has a market capitalization of 7.34 billion. As of now, sales total 1,015 M while income totals 444,090 K. Its latest quarter income was 298,010 K while its last quarter net income were 137,010 K.
